Oseltamivir-resistant influenza A(H1N1)pdm2009 strains found in Brazil are endowed with permissive mutations, which compensate the loss of fitness imposed by antiviral resistance

Thiago Moreno Lopes e Souza1,2,3,*, Natalia Fintelman-Rodrigues1, Paola Cristina Resende1, Milene Mesquita1, Tatiana Schaffer Gregianini1, Fernando A Bozza5, Ana Carla Pecego5, Sandra Bianchini Fernandes6, Ana Luisa Furtado Cury7, Irina Nastassja Riediger8, Marilda M Siqueira1

1Laboratório de Vírus Respiratórios e do Sarampo, 2Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz
3Centro de Desenvolvimento Tecnológico em Saúde, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil
4Laboratório Central de Saúde Pública do Estado de São Paulo, São Paulo, SP, Brasil
5Laboratório Central de Saúde Pública do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brasil
6Laboratório Central de Saúde Pública do Estado de Santa Catarina, Florianópolis, SC, Brasil
7Laboratório Central de Saúde Pública do Estado de Minas Gerais, Instituto Octávio Magalhães, Fundação Ezequiel Dias, Belo Horizonte, MG, Brasil
8Laboratório Central de Saúde Pública do Estado do Paraná, Curitiba, PR, Brasil

The 2009 pandemic influenza A virus outbreak led to the systematic use of the neuraminidase (NA) inhibitor oseltamivir (OST). Consequently, OST-resistant strains, carrying the mutation H275Y, emerged in the years after the pandemics, with a prevalence of 1-2%. Currently, OST-resistant strains have been found in community settings, in untreated individuals. To spread in community settings, H275Y mutants must contain additional mutations, collectively called permissive mutations. We display the permissive mutations in NA of OST-resistant A(H1N1)pdm09 virus found in Brazilian community settings. The NAs from 2013 are phylogenetically distinct from those of 2012, indicating a tendency of positive selection of NAs with better fitness. Some previously predicted permissive mutations, such as V241I and N369K, found in different countries, were also detected in Brazil. Importantly, the change D344N, also predicted to compensate loss of fitness imposed by H275Y mutation, was found in Brazil, but not in other countries in 2013. Our results reinforce the notion that OST-resistant A(H1N1)pdm09 strains with compensatory mutations may arise in an independent fashion, with samples being identified in different states of Brazil and in different countries. Systematic circulation of these viral strains may jeopardise the use of the first line of anti-influenza drugs in the future.

Key words: influenza A(H1N1)pdm09 - oseltamivir - antiviral - resistance - H275Y - permissive mutation

Anti-influenza drugs are essential for prophylactic and therapeutic interventions. Since antiviral resistance to adamantanes is very common (Santesso et al. 2013), neuraminidase inhibitors (NAI) have become the main class of anti-influenza drugs in clinical use. Among NAIs, oseltamivir (OST) use has grown since the emergence of 2009 pandemic influenza A [A(H1N1)pdm09]. Consequently, the pressure imposed by OST on A(H1N1) pdm09 has led to the selection of OST-resistant mutants, with a prevalence of 1-2% in different countries (Dixit et al. 2013). Remarkably, community transmission of OST-resistant influenza A(H1N1)pdm09 has drawn special attention because mutation H275Y in the neuraminidase (NA) may decrease viral fitness (Kelso & Hurt 2012). Nevertheless, the H275Y change may emerge in a NA endowed with permissive mutations (Kelso & Hurt 2012), which compensates for the decrease in viral fitness imposed by OST resistance. Viral strains carrying predicted permissive mutations have been circulating (Hurt et al. 2011, 2012, Kelso & Hurt 2012, CDC 2013, Takashita et al. 2014, Zaraket et al. 2014, Correia et al. 2015) and may have been responsible for A(H1N1) pdm09 OST-resistant outbreaks in community settings (Hurt et al. 2011, 2012, Lackenby et al. 2011, Kelso & Hurt 2012, Storms et al. 2012, CDC 2013, Souza et al. 2013, Takashita et al. 2014, Zaraket et al. 2014, Correia et al. 2015). The largest cluster of community spread of OST-resistant A(H1N1)pdm09 occurred in Australia, with cases detected in cities 4,000 km apart (Hurt et al. 2011, 2012). In Brazil during 2012, we found an overall incidence of 1.19% of OST-resistant strains of influenza A(H1N1)pdm09 surveillance data reveals the circulation of OST-resistant strains with predicted permissive mutations, detected by Sanger sequencing, in community settings in Brazil.

SUBJECTS, MATERIALS AND METHODS

Ethics - Since influenza surveillance is covered by Brazilian public health policies and all data were analysed in an anonymous fashion, ethical committee approval and need for informed consent have been waived, as previously described (Souza et al. 2013).
Patients and data collection - A sub-set of samples from patients displaying acute symptoms of respiratory infection (fever, > 37.8°C and respiratory influenza-like illness) (WHO 2011) were collected and sent to the National Influenza Centre (NIC) in Brazil. Patients were treated according to Brazilian guidelines for influenza management (MS 2009). Patients’ information, such as name initials, gender, age, city/state of onset of illness and the dates of the beginning of the symptoms and sample collection, were registered.

Sample collection and diagnosis - Nasopharyngeal aspirates or Dacron swabs were collected and RNA was extracted using a viral RNA mini kit (QIAGEN, USA), according to the manufacturer’s instructions. One-step real-time reverse transcription-polymerase chain reaction (RT-PCR) assays for influenza subtyping were performed according to the World Health Organization (WHO) recommendations (WHO 2011).

Cells and virus isolation - Madin-Darby canine kidney cells (London line) were kindly donated by the Centers of Disease Control and Prevention (CDC), Influenza Reagent Resources (FR-58). These cells were cultured in Dulbecco’s modified Eagle’s medium (GIBCO, USA) supplemented with 10% foetal bovine serum (HyClone, USA), 100 U/mL penicillin and 100 µg/mL streptomycin and were incubated at 37°C in 5% CO2 (WHO 2011). The virus isolation was done according to WHO international protocol (WHO 2011). We confirmed viral isolation by NA activity (Szretter et al. 2006, WHO 2009, 2011). Viruses were passaged no more than two times.

Functional antiviral assay - To determine the half maximum inhibitory concentration (IC50) values of our samples to OST carboxylate, we performed functional antiviral assays using the NA-Star™ assay kit (Life Technologies, USA), according to the manufacturer’s instructions (Souza et al. 2013). Assays with wild-type and resistant strains of influenza A(H1N1)pdm09, A/Perth/265/2009 and A/Perth/261/2009, respectively, were performed as a control. These control strains were kindly donated by International Society for Influenza and other Respiratory Viruses Diseases-Antiviral Group, Neuraminidase Inhibitor Susceptibility Network.

Molecular antiviral assays - Single nucleotide polymorphisms in the NA gene were analysed by pyrosequencing, as described previously (Deyde et al. 2010).

The NA gene was sequenced by Sanger sequencing according to a protocol described elsewhere (Baillie et al. 2012). The amplified RT-PCR products were purified using the QIAquick PCR Purification kit (QIAGEN) and sequenced using a BigDye Terminator v.3.1 Cycle Sequencing kit (Life Technologies). The products were analysed in an ABI Prism 3130XL genetic analyser (Life Technologies). Sequences with the mutation H275Y found in our analysis were deposited in GenBank (accessions KC984901, KC984933, KJ493404 and KJ493405). The data generated were assembled in Sequencher 5.0 software (GeneCodes Corporation, USA) with an NA reference sequence, A/California/4/2009 (GenBank accession FJ966084). NI numbering was used for NA throughout this study.

RESULTS AND DISCUSSION

In 2013, the Brazilian NIC received 1,498 specimens from individuals with acute respiratory infection, encompassing samples from three out of five Brazilian Regions. Among these, 310 were positive for influenza virus A(H1N1)pdm09. Most of the cases were concentrated in the southern (52.9%) and southeastern (31.3%) regions of Brazil. The analysed samples were collected mainly during autumn (28.4%) and winter (36.1%). Based on clinical-epidemiological forms completed, symptoms of severe acute respiratory infection were found in 2% of the patients, vaccines accounted for 13.5% of the individuals, comorbidities were registered in 13.9% of the patients and 7.7% deceased. OST-treated patients accounted for 15.9% of the individuals analysed. Among all confirmed cases of A(H1N1)pdm09, 208 samples presented reliable pyrograms, with respect to screening for the H275Y mutation (Deyde et al. 2010). Two specimens contained A(H1N1)pdm09 virus with the H275Y amino acid substitution indicative for OST resistance were found (Table). These were from individuals with no registered use of OST (Table), as occurred in 2012 (Souza et al. 2013). The IC50 values for sensitive strains (n = 206) isolated in 2013 were 0.5 ± 0.4 nM (mean ± standard deviation) and the IC50 values for resistant strains were 102 and 116 nM (Table).

In general, viral strains found in Brazilian community settings from 2013 clustered in a different branch than those from 2012 (Fig. 1) (H275Y viruses in red). This temporal segregation of NA sequences may suggest a tendency of positive selection of A(H1N1)pdm09 NAs. It is therefore likely that viruses with these NAs are better adapted to propagate in their hosts than the predece-

| Patients | Mutations | IC50 (nM) | Region | State | Age | Gender | Symptoms onset (date) | Sample collection (date) | OST use | Deceased |
|----------|-----------|-----------|--------|-------|-----|--------|-----------------------|------------------------|---------|----------|
| 1        | H275Y     | 102       | Southeast | RJ    | 40  | F      | 2 April 2013          | 5 April 2013           | No      | No       |
| 2        | H275Y     | 116       | South   | RS    | 26  | F      | 26 March 2013         | 5 April 2013           | No      | No       |

IC50: the half maximum inhibitory concentration; OST: oseltamivir; RJ: Rio de Janeiro; RS: Rio Grande do Sul.
sor strains. The NA from Brazilian strains from 2012 and 2013 had the changes V241I and N369K in common. These mutations have been found in Brazil since 2011 (Fig. 1) and are predicted to compensate for the negative effects of H275Y change (Hurt et al. 2012, Butler et al. 2014). The V241I and N369K enhance NA expression and activity in in vitro studies and this effect improve A(H1N1)pdm09 fitness (Butler et al. 2014). These two changes have also been found in the community cluster of OST-resistant A(H1N1)pdm09 in the United States of America (USA), Australia and Japan (Hurt et al. 2012, CDC 2013, Takashita et al. 2014). The permissive mutation N386K, on the other hand, was found in Australia and Japan (Hurt et al. 2012, Takashita et al. 2014), but not in the Americas (neither in USA or Brazil). Differently than Australian samples, Japanese, North American and Brazilian samples from 2013 had the change N200S (Storms et al. 2012, Takashita et al. 2014). Remarkably, one Brazilian sample from 2013 had the change D344N, which is predicted to occur in A(H1N1)pdm09 NA by in silico data and capable of compensating for the reduction in NA activity by H275Y (Bloom et al. 2011). In addition, other changes of apparently minor importance occurred in the NA sequences shown in red in the phy-
logenetic tree (Fig. 1) (GenBank accessions KC984901, KC984933, KJ493404 and KJ493405). For example, the mutations N42S (2012) and N44S (2013) may create new glycosylation sites (Hurt et al. 2012). Moreover, we also found mutations in the A(H1N1)pdm09 NA close to their equivalent amino acid residues in the widely disseminated OST-resistant seasonal H1N1 (Meijer et al. 2007, Hurt et al. 2009, 2012); such as S79P, I188T and N225D.

For public health concerns, H275Y viruses from 2012 were found in the cities of Foz do Iguaçu (state of Paraná) and Florianópolis (state of Santa Catarina) (Souza et al. 2013), whereas the two samples from 2013 were collected in Nova Iguaçu (NIG) (state of Rio de Janeiro) and Porto Alegre (POA) (state of Rio Grande do Sul) (Fig. 2). NIG and POA are cities around 1,490 km apart and have population densities of 1,527.60 and 2,837.52 inhabitant/km² (IBGE 2010), respectively. High population densities, such as these, increase the risk of respiratory virus infection and highlight the potential to spread OST-resistant variants. Considering the data from 2012 and 2013, an area of over 271,817 km² could be exposed to OST-resistant A(H1N1)pdm09 found in community settings. Remarkably, this area is within the southern and southeastern Brazilian regions, in which influenza activities are higher due to transition from a temperate to tropical climate.

Our data not only suggests that OST-resistant strains may be present in an even broader area of Brazil or South America, than previously thought (Souza et al. 2013), but also draws special attention to the community detection of influenza A(H1N1)pdm09 H275Y in highly populous developing countries in which antiviral resistance surveillance may be neglected. Although low prevalence of H275Y viruses with permissive mutations in the NA is comparable to what is found in other countries, this information is critical for further drug stockpiling and pandemic preparedness.

ACKNOWLEDGEMENTS

To IOC/Fiocruz, for providing PCR and NFR fellowships, and to Ms Sharon Carney, for reviewing the paper.

REFERENCES

Baillie GJ, Galiano M, Agapow PM, Myers R, Chiam R, Gall A, Palsger AL, Watson SJ, Hedge J, Underwood A, Platt S, McLean E, Pebody RG, Rambaut A, Green J, Daniels R, Pybus OG, Kellam P, Zambon M 2012. Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis. J Virol 86: 11-18.

Bloom JD, Nayak JS, Baltimore D 2011. A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. PLoS ONE 6: e22201.

Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, Guar naccia T, Baas C, Xue L, Vitesnik S, Leang SK, McVernon J, Kelso A, Barr IG, McCaw JM, Bloom JD, Hurt AC 2014. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog 10: e1004065.

CDC - Centers for Disease Control and Prevention 2013. Weekly U.S. Influenza Surveillance Report. FluView. A weekly influenza surveillance report prepared by the Influenza Division. 2013-2014 influenza season week 51 ending December 21, 2013. Available from: cdc.gov/flu/weekly/.

Correia V, Santos LA, Giria M, Almeida-Santos MM, Rebelo-de-Andre H 2015. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs. J Med Virol 87: 45-56.
Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, Gubareva LV 2010. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. *Antimicrob Agents Chemother* 54: 1102-1110.

Dixit R, Khandaker G, Igoutz S, Rashid H, Booy R 2013. Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. *Infect Disord Drug Targets* 13: 34-45.

Hurt AC, Earnest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D, Guigon A, Harrower B, Kei JP, Kok T, Lin C, McPhie K, Mohd A, Olveda R, Panayotou T, Rawlinson W, Scott L, Smith D, D'Souza H, Komadina N, Shaw R, Kelso A, Barr IG 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. *Antiviral Res* 83: 90-93.

Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N, Kelso A 2011. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. *N Engl J Med* 365: 2541-2542.

Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, Wark P, Caldwell N, Gyinvey RC, Xue L, Maurer-Stroh S, Dwyer DE, Wang B, Smith DW, Levy A, Booy R, Dixit R, Merritt T, Kelso A, Dalton C, Durhime D, Barr IG 2012. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. *J Infect Dis* 206: 148-157.

IBGE - Instituto Brasileiro de Geografia e Estatística 2010. Censo 2010. Available from: censo2010.ibge.gov.br.

Kelso A, Hurt AC 2012. The ongoing battle against influenza: drug-resistant influenza viruses: why fitness matters. *Nat Med* 18: 1470-1471.

Lackenby A, Gilad JM, Pebody R, Miah S, Calatayud L, Bolotin S, Vipond I, Muir P, Guiver M, McMenamin J, Reynolds A, Moore C, Gunson R, Thompson C, Galiano M, Bermingham A, Ellis J, Zambon M 2011. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. *Euro Surveill* 16: 19784.

Meijer A, Lackenby A, Hay A, Zambon M 2007. Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. *Euro Surveill* 12: E3-E4.

MS - Ministério da Saúde Brasil 2009. *Protocolo de manejo clínico e vigilância epidemiológica da influenza, versão III*, MS, Brasília, 32 pp.

Santesso N, Hsu J, Mustafa R, Brozek J, Chen YL, Hopkins JP, Cheung A, Hovhannisyan G, Ivanova L, Flottorp SA, Saeterdal I, Wong AD, Tian J, Uyeki TM, Akl EA, Alonso-Coello P, Smail F, Schünemann HJ 2013. Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies. *Influenza Other Respir Viruses* 7 (Suppl. 2): 76-81.

Souza TM, Resende PC, Fintelman-Rodrigues N, Gregiani T, Ikuta N, Fernandes SB, Cury AL, Rosa MC, Siqueira MM 2013. Detection of oseltamivir-resistant pandemic influenza A(H1N1) pdm2009 in Brazil: can community transmission be ruled out? *PLoS ONE* 8: e80081.

Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisdorf E, George KS, Myers R, Wotton JT, Robinson S, Leader B, Thompson M, Shannon M, Klimov A, Fry AM 2012. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. *Emerg Infect Dis* 18: 308-311.

Szretter KJ, Balish AL, Katz JM 2006. Influenza: propagation, quantification and storage. *Curr Protoc Microbiol* 3: C15-U15G.1.

Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, Nishimura H, Odagiri T, Tashiro M 2014. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. *Emerg Infect Dis* 19: 20666.

WHO - World Health Organization 2009. CDC protocol of realtime RTPCR for influenza A(H1N1). Available from: who.int/csr/resources/publications/swineflu/realtimeptpcr/en/.

WHO - World Health Organization 2011. *WHO Global Influenza Network 2011. Manual for the laboratory diagnosis and virological surveillance of influenza*, WHO, Geneva, 139 pp.

Zaraket H, Dapat C, Ghnem S, Ali Z, Lteif M, Kondo H, Dapat IC, Saito K, Kayali G, Suzuki H, Dibaqo B, Saito R 2014. Characterization of human influenza viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons. *Intervirology* 57: 344-352.